Table 2—

Characteristics of case and control subjects

Case subjectsControl subjectsP
n1091,044
Age (years)48.5 ± 4.648.0 ± 4.80.42
Duration of follow-up (years)4.1 ± 2.04.1 ± 2.50.81
NAFLD (%)59.625.0<0.001
Metabolic syndrome (%)7.36.10.62
Current smoker (%)55.053.10.69
Regular physical activity at least once a week (%)54.157.90.45
BMI (kg/m2)23.5 ± 2.423.4 ± 2.50.83
Body fat (%)21.4 ± 4.921.6 ± 4.50.72
Systolic blood pressure (mmHg)127 ± 16126 ± 150.58
Diastolic blood pressure (mmHg)78 ± 1179 ± 110.43
75-g oral glucose tolerance test
    Fasting plasma glucose (mmol/l)5.2 ± 0.45.2 ± 0.40.38
    1-h plasma glucose (mmol/l)9.5 ± 1.97.9 ± 1.9<0.001
    2-h plasma glucose (mmol/l)6.3 ± 1.06.1 ± 1.00.02
A1C (%)5.0 ± 0.44.9 ± 0.40.001
Total cholesterol (mmol/l)5.1 ± 0.85.2 ± 0.80.35
HDL cholesterol (mmol/l)1.3 ± 0.41.4 ± 0.40.002
Triglyceride (mmol/l)1.5 ± 0.71.4 ± 0.90.49
Aspartate aminotransferase (IU/l)25 ± 923 ± 70.03
Alanine aminotransferase (IU/l)30 ± 1727 ± 160.03
γ-Glutamyltransferase (IU/l)44 ± 3040 ± 260.08
Alkaline phosphatase (IU/l)151 ± 41166 ± 510.002
  • Data are means ± SD or percent of subjects.